Axogen, Inc.
For the period ended Sep 30, 2026. Filed Oct 28, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 28, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
During the three months ended September 30, 2026, our Section 16 officers and directors adopted orterminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” as such terms are defined under Item 408 of Regulation S-K as noted below.
| Name and Title | Action | Date | Trading Arrangement | Aggregate Number of Securities to be Sold | Expiration Date |
|---|---|---|---|---|---|
| Rule 10b5-1 (1) · Non-Rule 10b5-1 (2) | |||||
| Erick DeVinney, Chief Scientific Officer | Adopt | September 16, 2026 | X | 93,039 | December 16, 2027 |
(1)Intended to satisfy the affirmative defense of Rule 10b5-1(c).
(2)Not intended to satisfy the affirmative defense of Rule 10b5-1(c).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.